Drug Pipeline Insights Report
3 new drugs to watch this fall
Are these new gene therapies worth the price?
By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: October 2022
Welcome to the fall edition of Drugs to Watch.
As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision this fall.
Two of the three drugs discussed have an Orphan Drug designation while the third was granted Priority Review. In today's market, we are seeing new orphan drugs more frequently and expect this trend to continue. However, you may be surprised by the price tag.
The drugs in this report include treatments for:
- Kidney disease
- Inherited bleeding disorder
- Eye disease
Don't want to read the full report? Download the brief summary.
Related content
Gene therapy: How to prepare for a growing pipeline
The unprecedented cost of gene therapies requires a fundamental rethinking of how treatment costs are managed.
8 ways to make drugs more affordable
Discover what plan sponsors need to know.
5 questions: Optum Rx chief pharmacy officer
Michael Einodshofer addresses the risks, challenges and opportunities facing the industry.
Top